The GLP-1R/GIPR dual-agonist tirzepatide has demonstrated a remarkable 23% body weight reduction in individuals with obesity over 72 weeks, eclipsing the average result achieved by certain bariatric surgery [78]
Novo Nordisk A/S Sanofi Future Outlook The future prospects of the GLP-1 analogues market seem promising due to the growing demand for the treatments against diabetes, obesity, and other metabolic diseases
pubmed.ncbi.nlm.nih.gov/35658024 Cani PD, Lecourt E, Dewulf EM, et al
Blood glucose First, the participants finger was cleansed with an alcohol pad, allowed to dry, then punctured with a disposable lancet
Particles or floaters: Hold the vial up to a light source and look carefully
L.HyvarinenN.LillyN.KayK.DossatA.PariseE.et al